Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines for patients with autoimmune diseases, blood cancers and genetic diseases. The company is developing a suite of antibody-drug conjugates (ADCs), for conditioning. The company's main conditioning product candidate, MGTA-117, is designed to specifically remove disease-causing hematopoietic stem cells and genetically mutated cells. The company's third ADC-based conditioning program, C300, targets T cells, a type of immune cell. The company is also developing MGTA-145 as the standard of care for stem cell mobilization in a range of diseases, including autoimmune diseases, genetic diseases and blood cancers.
  • TickerMGTA
  • ISINUS55910K1088
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 14 2021 6:52AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

Wedbush PacGrow Healthcare Conference

Wedbush Research

Wedbush Morning Call - Jun 07 2021 6:57AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 14 2021 6:52AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

Wedbush PacGrow Healthcare Conference

Wedbush Research

Wedbush Morning Call - Jun 07 2021 6:57AM

ResearchPool Subscriptions

Get the most out of your insights

Get in touch